JP2017501137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501137A5 JP2017501137A5 JP2016535646A JP2016535646A JP2017501137A5 JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5 JP 2016535646 A JP2016535646 A JP 2016535646A JP 2016535646 A JP2016535646 A JP 2016535646A JP 2017501137 A5 JP2017501137 A5 JP 2017501137A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- biomarker
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 61
- 239000000090 biomarker Substances 0.000 claims description 53
- 208000026310 Breast neoplasm Diseases 0.000 claims description 43
- 206010006187 Breast cancer Diseases 0.000 claims description 41
- 229940121396 wnt pathway inhibitor Drugs 0.000 claims description 36
- 102100021411 C-terminal-binding protein 2 Human genes 0.000 claims description 20
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 20
- 102100028146 F-box/WD repeat-containing protein 2 Human genes 0.000 claims description 20
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims description 20
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 20
- 101001060245 Homo sapiens F-box/WD repeat-containing protein 2 Proteins 0.000 claims description 20
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims description 20
- 101000666661 Homo sapiens Rho-related GTP-binding protein RhoU Proteins 0.000 claims description 20
- 101000665937 Homo sapiens Wnt inhibitory factor 1 Proteins 0.000 claims description 20
- 102100038399 Rho-related GTP-binding protein RhoU Human genes 0.000 claims description 20
- 102100038258 Wnt inhibitory factor 1 Human genes 0.000 claims description 20
- 101150052649 ctbp2 gene Proteins 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 16
- 102100028466 Frizzled-8 Human genes 0.000 claims description 12
- 101100447415 Homo sapiens FZD8 gene Proteins 0.000 claims description 12
- 101000819438 Homo sapiens Frizzled-1 Proteins 0.000 claims description 12
- 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 claims description 12
- 101000885585 Homo sapiens Frizzled-5 Proteins 0.000 claims description 12
- 101000885797 Homo sapiens Frizzled-7 Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102000046612 human FZD1 Human genes 0.000 claims description 12
- 102000046609 human FZD2 Human genes 0.000 claims description 12
- 102000046146 human FZD5 Human genes 0.000 claims description 12
- 102000055611 human FZD7 Human genes 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 230000004043 responsiveness Effects 0.000 claims description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 238000003559 RNA-seq method Methods 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 229940028652 abraxane Drugs 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000007717 exclusion Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910663P | 2013-12-02 | 2013-12-02 | |
| US61/910,663 | 2013-12-02 | ||
| US201461975339P | 2014-04-04 | 2014-04-04 | |
| US61/975,339 | 2014-04-04 | ||
| PCT/US2014/068097 WO2015084808A1 (en) | 2013-12-02 | 2014-12-02 | Identification of predictive biomarkers associated with wnt pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501137A JP2017501137A (ja) | 2017-01-12 |
| JP2017501137A5 true JP2017501137A5 (enExample) | 2018-01-18 |
Family
ID=53274023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535646A Pending JP2017501137A (ja) | 2013-12-02 | 2014-12-02 | Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3077546A4 (enExample) |
| JP (1) | JP2017501137A (enExample) |
| CN (1) | CN105829547A (enExample) |
| AU (1) | AU2014357354A1 (enExample) |
| CA (1) | CA2931975A1 (enExample) |
| HK (1) | HK1223657A1 (enExample) |
| MX (1) | MX2016007066A (enExample) |
| TW (1) | TW201610168A (enExample) |
| WO (1) | WO2015084808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| US20180223372A1 (en) * | 2015-08-03 | 2018-08-09 | Oncomed Pharmaceutical, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| EP3349751A4 (en) * | 2015-09-16 | 2019-05-22 | Tobira Therapeutics, Inc. | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS |
| WO2018081437A1 (en) * | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CN106990245B (zh) * | 2017-04-05 | 2018-07-31 | 东南大学 | 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| CN110835372B (zh) * | 2019-11-06 | 2020-12-01 | 上海健康医学院 | 一种靶向Frizzled7单克隆抗体及其制备方法与应用 |
| JP7593584B2 (ja) * | 2020-03-10 | 2024-12-03 | 学校法人杏林学園 | 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN115337400A (zh) * | 2021-05-13 | 2022-11-15 | 中国科学院分子细胞科学卓越创新中心 | 诊断和治疗肿瘤的试剂及其用途 |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| WO2023113013A1 (ja) * | 2021-12-17 | 2023-06-22 | 国立大学法人京都大学 | 疾患発症の可能性の推定を行う遺伝子の選別方法及び疾患発症の可能性を推定する方法 |
| WO2024189200A1 (en) * | 2023-03-15 | 2024-09-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Cancer stratification and treatment |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP1194549A2 (en) * | 1999-07-02 | 2002-04-10 | Chiron Corporation | Human genes and gene expression products |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| AU2002248184C1 (en) | 2000-12-12 | 2018-01-04 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1549144A4 (en) * | 2002-10-04 | 2010-01-06 | Univ California | METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2004290070A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| EP1945754B1 (en) | 2005-10-31 | 2014-07-23 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| AU2007292242A1 (en) | 2006-09-08 | 2008-03-13 | Genentech, Inc. | Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders |
| WO2008039071A2 (en) * | 2006-09-29 | 2008-04-03 | Agendia B.V. | High-throughput diagnostic testing using arrays |
| PL2066694T3 (pl) | 2006-09-29 | 2016-04-29 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworu |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| EP2275431A3 (en) | 2008-01-18 | 2011-05-25 | Bio-Rad Laboratories, Inc. | Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography |
| CA2738485A1 (en) * | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| US20100169025A1 (en) * | 2008-10-10 | 2010-07-01 | Arthur William T | Methods and gene expression signature for wnt/b-catenin signaling pathway |
| WO2010101793A2 (en) * | 2009-03-06 | 2010-09-10 | University Of South Alabama | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| EP2523974A4 (en) | 2010-01-12 | 2013-11-06 | Oncomed Pharm Inc | WNT BINDER AND APPLICATIONS THEREOF |
| US20150132301A1 (en) * | 2011-12-09 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Combination Therapy for Treatment of Cancer |
-
2014
- 2014-12-02 MX MX2016007066A patent/MX2016007066A/es unknown
- 2014-12-02 AU AU2014357354A patent/AU2014357354A1/en not_active Abandoned
- 2014-12-02 EP EP14867583.8A patent/EP3077546A4/en not_active Withdrawn
- 2014-12-02 CN CN201480065718.7A patent/CN105829547A/zh active Pending
- 2014-12-02 HK HK16111927.7A patent/HK1223657A1/zh unknown
- 2014-12-02 CA CA2931975A patent/CA2931975A1/en not_active Abandoned
- 2014-12-02 WO PCT/US2014/068097 patent/WO2015084808A1/en not_active Ceased
- 2014-12-02 TW TW103141799A patent/TW201610168A/zh unknown
- 2014-12-02 JP JP2016535646A patent/JP2017501137A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501137A5 (enExample) | ||
| Yan et al. | HER2 aberrations in cancer: implications for therapy | |
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| JP2016520289A5 (enExample) | ||
| JP6781184B2 (ja) | がん転移の予後診断および処置のための方法 | |
| JP2016539083A5 (enExample) | ||
| KR102571924B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| JP2014524746A5 (enExample) | ||
| ES2779309T3 (es) | Método para la cuantificación de PD-L1 | |
| JP2016533395A5 (enExample) | ||
| JP2018511611A5 (enExample) | ||
| JP2017517507A5 (enExample) | ||
| JP2008523073A5 (enExample) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| KR20160048196A (ko) | 교모세포종의 치료를 위한 진단 방법 및 조성물 | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| RU2016147398A (ru) | Способы оценивания и лечения острого миелоидного лейкоза | |
| WO2014151606A4 (en) | Methods of treating pancreatic cancer | |
| JP2019523641A5 (enExample) | ||
| JP2016105731A5 (enExample) | ||
| JP2018525994A5 (enExample) | ||
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| RU2018104570A (ru) | Экспрессия fgfr и чувствительность к ингибитору fgfr | |
| JP2015210268A5 (enExample) | ||
| JP2017527533A5 (enExample) |